TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11163735

Group type: EXPERIMENTAL
Intervention: Comprehensive local muscle training (aerobic resistance training, 1 hour, three times per week for 8 weeks)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 24
Study: 9286888

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 0
Study: 8360932

Group type: EXPERIMENTAL
Intervention: Daily supplementation with 14 vitamins and 12 minerals
Number of subjects: 3318

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3318
Study: 3532585

Group type: EXPERIMENTAL
Intervention: 3-HRSZ (3-month regimen)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 3-HRSZ3/3-HSZ2 (6-month regimen with two phases)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 6-HRSZ2 (6-month regimen, twice a week)
Number of subjects: 300
Study: 29872289

Group type: EXPERIMENTAL
Intervention: Water-based Liuzijue exercise (WG)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Land-based Liuzijue exercise (LG)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 50
Study: 27160118

Group type: EXPERIMENTAL
Intervention: Group Remifentanil (remifentanil 2 µg/kg followed by propofol 2 mg/kg)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Group Propofol (propofol 2 mg/kg followed by remifentanil)
Number of subjects: 84
Study: 24635387

Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Lercanidipine 10 mg
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Enalapril/Lercanidipine 20/10 mg combination
Number of subjects: 345
Study: 21793638

Group type: EXPERIMENTAL
Intervention: Tooth Guide Training Box (TTB)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Group Learning (GL)
Number of subjects: 71
Study: 20668035

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (IIT) targeting normal-for-age fasting blood glucose levels
Number of subjects: 700

Group type: COMPARATOR
Intervention: Insulin infusion only to prevent excessive hyperglycemia (Control)
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Patients experiencing hypoglycemia
Number of subjects: 700
Study: 18395305

Group type: EXPERIMENTAL
Intervention: Healive (new preservative-free inactivated hepatitis A vaccine)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control vaccine
Number of subjects: 400
Study: 15858105

Group type: EXPERIMENTAL
Intervention: Transcutaneous ablation of HCC with high-intensity focused ultrasound performed 2-4 weeks after TACE
Number of subjects: 50

Group type: COMPARATOR
Intervention: Transcatheter arterial chemoembolization (TACE) alone
Number of subjects: 50
Study: 11278231

Group type: EXPERIMENTAL
Intervention: Laparoscopic myomectomy
Number of subjects: 165

Group type: COMPARATOR
Intervention: Abdominal myomectomy
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Laparoscopic myomectomy (non-randomized group)
Number of subjects: 165
Study: 9641612

Group type: EXPERIMENTAL
Intervention: Hexarelin (HEX) 2.0 microg/kg i.v.
Number of subjects: 6

Group type: COMPARATOR
Intervention: Dexamethasone (DEXA) 1 mg p.o. at 23.00 h on the previous night
Number of subjects: 6

Group type: COMPARATOR
Intervention: Alprazolam (ALP) 0.02 mg/kg p.o. at -90 min
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Hexarelin (HEX)
Number of subjects: 6
Study: 8124322

Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2572857

Group type: EXPERIMENTAL
Intervention: dexfenfluramine (dF), 15 mg twice daily
Number of subjects: 822

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 822

Group type: EXPERIMENTAL
Intervention: dexfenfluramine (dF)
Number of subjects: 822
Study: 979068

Group type: EXPERIMENTAL
Intervention: Spirolactone (400 mg, 200 mg, or 300 mg orally daily)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Strophanthin (0.375 to 0.625 mg intravenously)
Number of subjects: 15
Study: 31070869

Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 927

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 927
Study: 28625370

Group type: EXPERIMENTAL
Intervention: Apixaban (according to standard AF dosing)
Number of subjects: 4000

Group type: COMPARATOR
Intervention: Aspirin 81mg daily
Number of subjects: 4000
Study: 24557584

Group type: EXPERIMENTAL
Intervention: PVI-directed fluid management (2 mL/kg/h crystalloid fluid infusion, rapid infusion of 250 mL colloid or crystalloid if PVI>13%)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non PVI-directed fluid management (4‐8 mL/kg/h crystalloid fluid infusion, quick fluid infusion if mean arterial BP<65 mmHg)
Number of subjects: 30
Study: 24073484

Group type: EXPERIMENTAL
Intervention: Announced inspections
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unannounced inspections (Control)
Number of subjects: 0
Study: 21736825

Group type: EXPERIMENTAL
Intervention: Salmon (2 × 120 g servings/week)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Salmon oil capsules (2, 4, or 6 capsules/day)
Number of subjects: 44
Study: 19418208

Group type: EXPERIMENTAL
Intervention: Osmotic-release methylphenidate
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Extended release amphetamine salts
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35

Group type: COMPARATOR
Intervention: Routine limited medication regimen
Number of subjects: 35
Study: 16364555

Group type: EXPERIMENTAL
Intervention: 17.5 mg cortisol injection
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 15291656

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 0
Study: 11115082

Group type: EXPERIMENTAL
Intervention: ACEI/ATRA therapy
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (atenolol, hydrallazine, or methyldopa)
Number of subjects: 41
Study: 8824965

Group type: EXPERIMENTAL
Intervention: Fluconazole (200-800 mg daily, mostly 400 mg)
Number of subjects: 30
Study: 1361311

Group type: EXPERIMENTAL
Intervention: 0.25 micrograms/kg DMED
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 0.5 micrograms/kg DMED
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 1.0 micrograms/kg DMED
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 2.0 micrograms/kg DMED
Number of subjects: 37

Group type: COMPARATOR
Intervention: 0 micrograms/kg DMED (Placebo)
Number of subjects: 37
Study: 6429693

Group type: EXPERIMENTAL
Intervention: Imipramine administered IV (12.5 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Imipramine administered orally (50 mg) after overnight fast
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Imipramine administered orally (50 mg) 30 min after eating a standardized breakfast
Number of subjects: 12
Study: 31545017

Group type: EXPERIMENTAL
Intervention: Sequential peeling with 70% GA followed by 20% SA biweekly for three months
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Sequential peeling and doxycycline PO100 mg BD for 1 month followed by 100 OD for 2 months
Number of subjects: 45

Group type: COMPARATOR
Intervention: Oral doxycycline
Number of subjects: 45
Study: 29678158

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) infusion at 0.5 μg/kg/h from induction of anaesthesia to extubation (Group D)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline infusion (Group C)
Number of subjects: 60
Study: 29194303

Group type: EXPERIMENTAL
Intervention: Autogenic Training (AT)
Number of subjects: 0
Study: 26023230

Group type: COMPARATOR
Intervention: Saline infusion (control) at 30% maximal voluntary contraction (MVC)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: NOS inhibition in young adults
Number of subjects: 20
Study: 24158154

Group type: EXPERIMENTAL
Intervention: Injection drug use
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Being Black
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Living on the streets
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Not being part of a close family in childhood
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 157
Study: 21393318

Group type: EXPERIMENTAL
Intervention: Discussion about discipline with physician
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Viewing the multimedia program
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Viewing the multimedia program and discussion with physician
Number of subjects: 259

Group type: COMPARATOR
Intervention: No discussion and no multimedia program
Number of subjects: 259
Study: 18310199

Group type: EXPERIMENTAL
Intervention: Concurrent administration of live attenuated influenza vaccine with measles‐mumps‐rubella vaccine and varicella vaccine
Number of subjects: 1245

Group type: COMPARATOR
Intervention: Separate administration of live attenuated influenza vaccine
Number of subjects: 1245
Study: 16699858

Group type: EXPERIMENTAL
Intervention: Continued lamivudine therapy (group A)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Discontinued lamivudine therapy (group B)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 74
Study: 12721263

Group type: EXPERIMENTAL
Intervention: Randomized Controlled Trials (RCTs)
Number of subjects: 3560

Group type: EXPERIMENTAL
Intervention: Nonrandomized Trials
Number of subjects: 3560
Study: 10634958

Group type: EXPERIMENTAL
Intervention: Version 16‐135‐1 (Prime & Bond(R) 2.1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Version 17‐17‐1 (Dyract Adhesive(R) PSA)
Number of subjects: 80
Study: 9033712

Group type: EXPERIMENTAL
Intervention: Oxiconazole cream (1%) applied once daily
Number of subjects: 79

Group type: COMPARATOR
Intervention: Ketoconazole cream (2%) applied once daily
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Oxiconazole cream (1%)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Ketoconazole cream (2%)
Number of subjects: 79
Study: 1482251

Group type: EXPERIMENTAL
Intervention: Sphygmomanometer, by a nurse, on supine position since 10 min, on the third day of hospitalization
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Automatic device (Dinamap), on supine position, every 5 min, during 30 min
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure (Spacelab 90202 every 15 min between 8 a.m. and 8 p.m.)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: UAE
Number of subjects: 64
Study: 6094103

Group type: EXPERIMENTAL
Intervention: Suloctidil (200 mg 3-times daily)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 3884691

Group type: EXPERIMENTAL
Intervention: Sodium restriction
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Weight reduction
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Sodium restriction and weight reduction
Number of subjects: 496
Study: 31332524

Group type: EXPERIMENTAL
Intervention: Home-based behavioral parent training
Number of subjects: 73
Study: 28185774

Group type: EXPERIMENTAL
Intervention: Harmonic focus (HF)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Conventional ligation (CL)
Number of subjects: 206
Study: 27519616

Group type: EXPERIMENTAL
Intervention: Mesorectal excision (ME) alone
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Mesorectal excision (ME) with lateral lymph node dissection (LLND)
Number of subjects: 472
Study: 24913488

Group type: EXPERIMENTAL
Intervention: Visibility Enhancement System (VES) with two configurations: two continuous red lines or a series of red crosses
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Visibility Enhancement System (VES)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No VES (control condition)
Number of subjects: 30
Study: 23990709

Group type: EXPERIMENTAL
Intervention: Test formulation of candesartan cilexetil 16 mg
Number of subjects: 24
Study: 20501356

Group type: EXPERIMENTAL
Intervention: 10mg alendronate + 500 mg calcium
Number of subjects: 16

Group type: COMPARATOR
Intervention: 500 mg calcium only
Number of subjects: 16
Study: 18769826

Group type: EXPERIMENTAL
Intervention: Protocol-based sedation (group P)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional treatment (group C)
Number of subjects: 40
Study: 16899486

Group type: EXPERIMENTAL
Intervention: Learning process with two CD-ROMs containing digital images of 30 cases for diagnosis.
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Learning process with two CD-ROMs containing digital images of 30 cases for diagnosis after selected background reading.
Number of subjects: 8
Study: 14504773

Group type: EXPERIMENTAL
Intervention: At-home mental health care
Number of subjects: 83
Study: 10693901

Group type: EXPERIMENTAL
Intervention: Shoulder Disability Questionnaire (SDQ)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Standardized exercise therapy
Number of subjects: 180
Study: 8787882

Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Ceftizoxime
Number of subjects: 150
Study: 1522792

Group type: EXPERIMENTAL
Intervention: Computer-generated reminders for influenza vaccination
Number of subjects: 4555

Group type: COMPARATOR
Intervention: Control group (no reminders)
Number of subjects: 4555
Study: 6315261

Group type: EXPERIMENTAL
Intervention: Ergonovine maleate administration
Number of subjects: 14

Group type: COMPARATOR
Intervention: Cold pressor testing
Number of subjects: 14

Group type: COMPARATOR
Intervention: Phenylephrine infusion
Number of subjects: 14

Group type: COMPARATOR
Intervention: Norepinephrine infusion after beta-blockade
Number of subjects: 14

Group type: COMPARATOR
Intervention: Phentolamine infusion at the highest tolerated dose
Number of subjects: 14
Study: 31832001

Group type: EXPERIMENTAL
Intervention: LB100
Number of subjects: 0
Study: 28159505

Group type: EXPERIMENTAL
Intervention: Digital health (DH) with sensor-enabled medicines for 4 or 12 weeks
Number of subjects: 57

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Digital health (DH) with sensor-enabled medicines
Number of subjects: 57
Study: 26488677

Group type: COMPARATOR
Intervention: Site-rated Hamilton Anxiety Scale (HAM-A)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Remote centralized raters' assessment of HAM-A
Number of subjects: 122
Study: 23936148

Group type: EXPERIMENTAL
Intervention: Folic acid/vitamin B12 (± B6)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo (± B6)
Number of subjects: 102
Study: 20693247

Group type: EXPERIMENTAL
Intervention: Pre-trial rehabilitation followed by surgery or medical care
Number of subjects: 1218
Study: 19185817

Group type: EXPERIMENTAL
Intervention: MuViCure (audiovisual stimulation)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: MusiCure (audio stimulation)
Number of subjects: 55

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 55
Study: 16422138

Group type: EXPERIMENTAL
Intervention: Yogic breathing and meditation intervention
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Qualitative interviews
Number of subjects: 47
Study: 14960519

Group type: EXPERIMENTAL
Intervention: Pan-colonic chromoscopy using 0.5% indigo carmine
Number of subjects: 260

Group type: COMPARATOR
Intervention: Targeted chromoscopy (control group)
Number of subjects: 260
Study: 11478588

Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 9610350

Group type: EXPERIMENTAL
Intervention: Qualitative assessment of the common femoral Doppler waveform
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Common femoral waveform analysis
Number of subjects: 73
Study: 8047814

Group type: EXPERIMENTAL
Intervention: 50 mg/day oral isosorbide-5-mononitrate retard
Number of subjects: 76

Group type: COMPARATOR
Intervention: Identical placebo
Number of subjects: 76
Study: 3054777

Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study: 5071699

Group type: EXPERIMENTAL
Intervention: Cloxacillin
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Sodium fusidate
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 37
Study: 31778222

Group type: EXPERIMENTAL
Intervention: Intensive therapy targeting a systolic blood pressure (SBP) of 120 mm Hg
Number of subjects: 2313

Group type: COMPARATOR
Intervention: Standard therapy targeting a systolic blood pressure (SBP) of 140 mm Hg
Number of subjects: 2313

Group type: EXPERIMENTAL
Intervention: Participants aged 75 years and older
Number of subjects: 2313

Group type: EXPERIMENTAL
Intervention: Participants younger than 75 years
Number of subjects: 2313

Group type: EXPERIMENTAL
Intervention: Stratified by age
Number of subjects: 2313
Study: 31344287

Group type: EXPERIMENTAL
Intervention: OSTRC Shoulder Injury Prevention Programme
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 44
Study: 28209506

Group type: EXPERIMENTAL
Intervention: Steroid injection plus splinting
Number of subjects: 52

Group type: COMPARATOR
Intervention: Steroid injection alone
Number of subjects: 52
Study: 25151027

Group type: EXPERIMENTAL
Intervention: GnRHa treatment for 6 months (Group 2A)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Complete laparoscopic excision of DIE (Group 1A)
Number of subjects: 159

Group type: COMPARATOR
Intervention: No treatment (Group 1A)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: GnRHa treatment for 6 months (Group 2B)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Incomplete surgical treatment (Group 1B)
Number of subjects: 159
Study: 23531019

Group type: EXPERIMENTAL
Intervention: Inpatient treatment
Number of subjects: 600

Group type: COMPARATOR
Intervention: Day hospital treatment
Number of subjects: 600
Study: 21665462

Group type: EXPERIMENTAL
Intervention: Combination therapy (FOLFIRI)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Single-agent irinotecan
Number of subjects: 89
Study: 19307374

Group type: COMPARATOR
Intervention: Ampicillin (1 g intravenously every 6 hours)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Ampicillin plus oral P1A recombinant beta-lactamase (8.2 mg every 6 hours)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Oral P1A recombinant beta-lactamase (8.2 mg every 6 hours)
Number of subjects: 36
Study: 16540279

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural training programme (exercise treatment plus cognitive-behavioural training)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Exercise treatment only (control group)
Number of subjects: 47
Study: 15228184

Group type: EXPERIMENTAL
Intervention: Intravenous adalimumab (1 mg/kg)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Subcutaneous adalimumab (1 mg/kg)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 10932067

Group type: EXPERIMENTAL
Intervention: rhu mAb‐E25
Number of subjects: 251

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 251
Study: 9118763

Group type: EXPERIMENTAL
Intervention: Lispro (0.15 U/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Regular human insulin
Number of subjects: 12
Study: 8511505

Group type: EXPERIMENTAL
Intervention: Phenoxymethylpenicillin (PEN), 2.4 million units twice daily for up to 14 weeks
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Phenoxymethylpenicillin (PEN)
Number of subjects: 170
Study: 3318454

Group type: EXPERIMENTAL
Intervention: Fenofibrate (100 mg, three times daily)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study: 30333494

Group type: EXPERIMENTAL
Intervention: SPINK1 targeting in the damaged TME
Number of subjects: 0
Study: 26496680

Group type: EXPERIMENTAL
Intervention: Micropulse vibration device used for 20 minutes daily
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (no micropulse vibration device)
Number of subjects: 58
Study: 25152506

Group type: EXPERIMENTAL
Intervention: Public-private collaboration involving joint community clinics and public health department nurses aiding in delivery at practices
Number of subjects: 8

Group type: COMPARATOR
Intervention: Usual care without public health department involvement
Number of subjects: 8
Study: 22541758

Group type: EXPERIMENTAL
Intervention: Cardiology care
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 70
Study: 20419161

Group type: EXPERIMENTAL
Intervention: Oral activated charcoal (oAC)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Oral activated charcoal (oAC) with artesunate (AS)
Number of subjects: 52
Study: 17311303

Group type: EXPERIMENTAL
Intervention: Duloxetine 60-120 mg
Number of subjects: 327

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 327
Study: 16870053

Group type: EXPERIMENTAL
Intervention: Coping Effectiveness Training (CET) intervention
Number of subjects: 348
Study: 12603234

Group type: EXPERIMENTAL
Intervention: Pro‐Change system (Manual intervention) with self-help workbook and three questionnaires at 3-month intervals
Number of subjects: 2471

Group type: EXPERIMENTAL
Intervention: Pro‐Change system plus three telephone calls (Phone intervention)
Number of subjects: 2471

Group type: EXPERIMENTAL
Intervention: Pro‐Change system plus three visits to the practice nurse (Nurse intervention)
Number of subjects: 2471

Group type: COMPARATOR
Intervention: Control group receiving standard self-help literature
Number of subjects: 2471
Study: 11374852

Group type: EXPERIMENTAL
Intervention: Increase in high-density lipoprotein cholesterol (HDL-C) by 6%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Decrease in triglyceride levels by 31%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reduction in triglycerides in patients with baseline triglycerides >200 mg/dL (from Bezafibrate Infarction Prevention trial)
Number of subjects: 0
Study: 8795482

Group type: EXPERIMENTAL
Intervention: Coronary stenting with standardised anticoagulation regimen (intravenous heparin, oral vitamin K antagonist, 100 mg aspirin twice daily)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Coronary stenting with standardised anticoagulation regimen
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (elective coronary balloon angioplasty)
Number of subjects: 30
Study: 7745993

Group type: EXPERIMENTAL
Intervention: Interleukin-2 (IL-2, 1 x 106 I.U./day)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Vaccine only
Number of subjects: 75
Study: 2950340

Group type: EXPERIMENTAL
Intervention: Manufacturer-developed gloved procedure
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nongloved procedure developed by clinic nursing staff
Number of subjects: 40